Last reviewed · How we verify
NCT06724237
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Phase 3 trial testing Autologous Hematopoietic Stem Cell Transplantation in Anaplastic Large Cell Lymphoma, ALK-Negative in 294 participants. Not yet recruiting.
30 April 2028
Quick facts
| Lead sponsor | Eastern Cooperative Oncology Group |
|---|---|
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 294 |
| Start date | 1 December 2024 |
| Primary completion | 30 April 2028 |
| Estimated completion | 1 December 2033 |
Drugs / interventions tested
- Autologous Hematopoietic Stem Cell Transplantation
- Best Practice
- Biospecimen Collection — full drug profile →
- Bone Marrow Aspiration — full drug profile →
- Bone Marrow Biopsy
- Computed Tomography
- High Dose Chemotherapy — full drug profile →
- Leukapheresis — full drug profile →
- Positron Emission Tomography
- Stem Cell Mobilization Therapy — full drug profile →
Conditions studied
- Anaplastic Large Cell Lymphoma, ALK-Negative — all drugs for Anaplastic Large Cell Lymphoma, ALK-Negative →
- Follicular Helper T-Cell Lymphoma — all drugs for Follicular Helper T-Cell Lymphoma →
- Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type — all drugs for Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type →
- Peripheral T-Cell Lymphoma, Not Otherwise Specified — all drugs for Peripheral T-Cell Lymphoma, Not Otherwise Specified →
Sponsor
Eastern Cooperative Oncology Group
Who can join
Adults 18 to 75, any sex, with Anaplastic Large Cell Lymphoma, ALK-Negative or Follicular Helper T-Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. Usual treatment after a complete response may include observation or high dose chemotherapy followed by an autologous stem cell transplant, however, it is not known if a transplant if beneficial. Giving chemotherapy before a stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. Stem cells removed prior to treatment are then returned to the patient to replace the blood forming cells that were destroyed by the chemotherapy. Giving high dose chemotherapy followed by an autologous stem cell transplant may be more effective compared to observation only in treating patients with peripheral T-cell lymphoma who have achieved a complete response after initial chemotherapy.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Survival trends in the era of novel therapies identify unmet needs in peripheral T-cell lymphoma: a national cancer database analysis.
Wang J, Gao Y, Bennani NN, Tiger YK, et al · · 2026 · PMID 42236669 · DOI 10.1038/s41408-026-01533-8 -
Autologous stem cell transplantation in major T-cell lymphoma entities: An analysis by the EBMT Lymphoma Working Party.
Shumilov E, Ngoya M, Berning P, Khvedelidze I, et al · · 2026 · PMID 41743267 · DOI 10.1002/hem3.70313
Verify or expand the search:
- PubMed search for NCT06724237
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Autologous Hematopoietic Stem Cell Transplantation
Trials testing the same drug.
- NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07353840 — T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR · recruiting
- NCT07253129 — Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort · recruiting
- NCT07106710 — ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma · Phase 2 · recruiting
Other recruiting trials for Anaplastic Large Cell Lymphoma, ALK-Negative
Currently open trials in the same condition.
- NCT02978625 — Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-mela · Phase 2 · active not recruiting
- NCT03113500 — Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma · Phase 2 · active not recruiting
Other Eastern Cooperative Oncology Group trials
Trials by the same sponsor.
- NCT07068074 — A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients · Phase 3 · not yet recruiting
- NCT07040280 — Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Pati · Phase 2 · not yet recruiting
- NCT07122492 — A Targeted Electronic Health Approach to Reduce Fear of Recurrence in Breast Cancer Survivors (FoRtitude) · NA · not yet recruiting
- NCT07085728 — Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatm · Phase 2 · not yet recruiting
- NCT06756607 — The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06724237 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eastern Cooperative Oncology Group
- Last refreshed: 9 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06724237.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing